TotalMarketCap

Inhibikase Therapeutics

IKTNasdaq United StatesHealth CareBiotechnology: Biological Products (No Diagnostic Substances)

Market cap

$201.629 M

$1.45 -7.67%

Close of 6 Nov 2026

As of 6 Nov 2026, Inhibikase Therapeutics (IKT) has a market capitalization of $201.6M. Market cap measures the value of outstanding equity at market prices; company totals combine applicable share classes. Prices and market caps come from Nasdaq, with financial fundamentals from SEC filings. See sources and calculation details.

Revenue

$0.00

#3616 by revenue

Earnings

-$48.3M

Loss-making

Shares outstanding

139,535,900

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 163 →
  1. #95Artiva BiotherapeuticsARTV$202.4M
  2. #96Palisade BioPALI$202.2M
  3. #97Inhibikase TherapeuticsIKT$201.6M
  4. #98CompugenCGEN$183.0M
  5. #99InvivydIVVD$171.6M

What if Inhibikase Therapeutics were worth as much as…

Open the what-if tool →

Gold $28.2T

$202,362.79

Per share 140,043× higher

Bitcoin $1.53T

$10,949.50

Per share 7,578× higher

Apple $5.02T

$35,946.18

Per share 24,876× higher

Or at a round number

$500.0M$1.00B$2.00B$5.00B

Where these numbers come from

Share counts and financials for Inhibikase Therapeutics are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Read the methodology.